Intersect ENT, Inc. (XENT) |
| 28.24 0 (0%) 04-24 15:47 |
| Open: | 28.25 |
| High: | 28.25 |
| Low: | 28.23 |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | -10.54 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 7.49 |
| Resistance 1: | 6.41 |
| Pivot price: | 5.29 |
| Support 1: | 5.24 |
| Support 2: | 4.52 |
| 52w High: | 28.25 |
| 52w Low: | 15.92 |
Intersect ENT, Inc. is a medical technology firm focused on ear, nose, and throat (ENT) solutions, operating within the United States. Its product portfolio includes: PROPEL, PROPEL Mini, and PROPEL Contour: These are steroid-eluting implants. PROPEL is designed to maintain the patency of surgically enlarged sinuses, while PROPEL Mini targets patients undergoing frontal sinus procedures. PROPEL Contour specifically addresses the frontal and maxillary sinus ostia, or passages, within the dependent sinuses. SINUVA: Another steroid-releasing implant, intended for patient care in a clinical office environment. VENSURE Navigable and Stand-alone balloon: A sterile, single-use balloon device that facilitates access to and treatment of the frontal, sphenoid, and maxillary ostia in adult patients via a trans-nasal method. CUBE Navigation System: A digital guidance system offering high-accuracy navigation for ENT and associated skull-base surgical interventions. The company, originally established as Sinexus, Inc. in 2003, rebranded to Intersect ENT, Inc. in November 2009. Its corporate headquarters are located in Menlo Park, California.
| EPS | 13.510 |
| Book Value | 21.850 |
| PEG Ratio | 2.58 |
| Gross Profit | 3.742 |
| Profit Margin (%) | 176.72 |
| Operating Margin (%) | 4.38 |
| Return on Assets (ttm) | 0.9 |
| Return on Equity (ttm) | 113.1 |
Wed, 24 Dec 2025
Google drops $4.75bn on data center and energy firm Intersect - IT Pro
Thu, 24 Apr 2025
XENT Stock Price, News & Analysis - Stock Titan
Sun, 27 Nov 2022
De Clercq Casper L. Net Worth (2026) - GuruFocus
Fri, 13 May 2022
Medtronic completes Intersect ENT acquisition - MassDevice
Wed, 26 Jan 2022
Ahead by more than a nose: Intersect study shows lower health care usage with sinus implant - BioWorld News
Thu, 28 Oct 2021
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe - Business Wire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |